Bernstein D I, Rheins L A
James N. Gamble Institute of Medical Research, Cincinnati, Ohio 45219.
Antiviral Res. 1994 Apr;23(3-4):225-33. doi: 10.1016/0166-3542(94)90020-5.
Models of UV radiation induced herpes labialis utilizing crude light sources have previously been used to examine the efficacy of antivirals. We sought to improve upon this model by using a solar simulator. Initial studies revealed that 13 of 34 (38%) subjects with a history of recurrent HSV labialis receiving three minimal erythema doses (MED's) of UV light developed herpes labialis. We next evaluated the effects of combined therapy with topical ACV and 348U87, a ribonucleotide reductase inhibitor, begun immediately after UV exposure for the prevention and treatment of herpes labialis. No significant reduction in the incidence or severity of herpes labialis was detected although the study was terminated after the interim analysis revealed no benefit, thus reducing the power to detect a difference. This lack of effect may be explained by the general poor efficacy of topical treatment for recurrent HSV infection. Further studies of ACV + 348U87 in vehicles that should increase the penetration and stability of the drugs are planned.
此前曾使用利用粗光源的紫外线辐射诱发唇疱疹模型来检验抗病毒药物的疗效。我们试图通过使用太阳模拟器来改进这一模型。初步研究显示,34名有复发性唇疱疹病史的受试者中,13人(38%)接受三次最小红斑量(MED)的紫外线照射后患上唇疱疹。接下来,我们评估了紫外线照射后立即开始联合使用外用阿昔洛韦(ACV)和核糖核苷酸还原酶抑制剂348U87预防和治疗唇疱疹的效果。尽管中期分析显示无益处后研究即终止,从而降低了检测差异的效力,但未检测到唇疱疹的发病率或严重程度有显著降低。这种缺乏效果的情况可能是由于局部治疗复发性单纯疱疹病毒感染的总体疗效较差所致。计划进一步研究ACV + 348U87在能够提高药物渗透性和稳定性的载体中的效果。